Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

 
• By Joseph Haas

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

New direction
Cidara divests its antifungal and unveils a new corporate direction • Source: Shutterstock

More from Strategy

More from Business